News & Updates

Systemic treatment for metastatic melanoma might be beneficial in older patients

21 Sep 2021

Systemic melanoma treatment does not lead to increased toxicity in older adults and may yield slight survival benefits, a recent study has found. Nevertheless, death from causes other than melanoma contributes to a lower overall survival (OS) in older patients.

Systemic treatment for metastatic melanoma might be beneficial in older patients

21 Sep 2021

Original New Drug Application Approvals by US FDA (01-15 September 2021)

20 Sep 2021

New drug applications approved by US FDA as of 01-15 September 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01-15 September 2021)

20 Sep 2021

Prophylactic antibiotics cut risk of infectious complications following transbronchial biopsy

19 Sep 2021

For patients undergoing radial endobronchial ultrasound-guided transbronchial biopsy, use of prophylactic antibiotics leads to a lower incidence of infectious complications in the presence of risk factors, according to a study.

Prophylactic antibiotics cut risk of infectious complications following transbronchial biopsy

19 Sep 2021

Tisagenlecleucel shows durable activity in R/R aggressive large B-cell lymphomas

19 Sep 2021 by

The CD19-directed chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel has demonstrated durable activity and a manageable safety profile in adult patients with relapsed or refractory (R/R) aggressive large B-cell lymphomas (LBCLs) after long-term follow-up of the JULIET trial.

Tisagenlecleucel shows durable activity in R/R aggressive large B-cell lymphomas

19 Sep 2021

Statin does not prevent recurrence in high-risk patients undergoing prostatectomy

18 Sep 2021

Use of atorvastatin for a year appears to confer no benefit for the risk of disease recurrence among prostate cancer patients with high-risk pathologic features who have undergone radical prostatectomy, a study has found.

Statin does not prevent recurrence in high-risk patients undergoing prostatectomy

18 Sep 2021

Family history of Barrett's oesophagus, OAC a strong risk factor for each disease

17 Sep 2021

Individuals with a family history of Barrett's oesophagus or oesophageal adenocarcinoma (OAC) are at risk of developing the said diseases, according to the results of a systematic review and meta-analysis.

Family history of Barrett's oesophagus, OAC a strong risk factor for each disease

17 Sep 2021

Lenvatinib-pembrolizumab improves OS, PFS in advanced endometrial carcinoma regardless of DNA MMR status

16 Sep 2021 by

The combination of lenvatinib and pembrolizumab improved progression-free survival (PFS) and overall survival (OS) compared with physician’s choice of treatment (TPC) among patients with advanced endometrial cancer with prior exposure to platinum-based therapy, regardless of DNA mismatch repair (MMR) status, according to results of a phase III study presented at IGCS 2021.

Lenvatinib-pembrolizumab improves OS, PFS in advanced endometrial carcinoma regardless of DNA MMR status

16 Sep 2021

Apalutamide plus ADT effective against pain, fatigue in metastatic prostate cancer

16 Sep 2021 by

Treatment with apalutamide plus androgen deprivation therapy (ADT) results in consistently favourable pain scores and less interference from pain in the daily lives of patients with metastatic castration-sensitive prostate cancer compared with placebo plus ADT, results of the phase III TITAN study have shown. Moreover, there was no difference for change seen in fatigue with apalutamide vs placebo.

Apalutamide plus ADT effective against pain, fatigue in metastatic prostate cancer

16 Sep 2021

Pembrolizumab may alter adjuvant treatment landscape of kidney cancer

16 Sep 2021 by

The use of pembrolizumab significantly improved disease-free survival (DFS) in patients with clear-cell renal cell carcinoma (RCC) who have undergone nephrectomy, with or without metastasectomy, and were at high risk for recurrence, according to the phase III KEYNOTE-564 trial.

Pembrolizumab may alter adjuvant treatment landscape of kidney cancer

16 Sep 2021

CLAM in R/R AML: High response rates, effective bridge to allo-HSCT

15 Sep 2021 by

One cycle of clofarabine, cytarabine and mitoxantrone (CLAM) achieves an overall response rate (ORR) of >90 percent with a complete remission (CR) rate of nearly 70 percent in a phase II study of Hong Kong patients with refractory/relapsed acute myeloid leukaemia (R/R AML).

CLAM in R/R AML: High response rates, effective bridge to allo-HSCT

15 Sep 2021

News & Updates

Filter by Specialty:

Specialty:

Systemic treatment for metastatic melanoma might be beneficial in older patients

Systemic treatment for metastatic melanoma might be beneficial in older patients

Original New Drug Application Approvals by US FDA (01-15 September 2021)

Original New Drug Application Approvals by US FDA (01-15 September 2021)

Prophylactic antibiotics cut risk of infectious complications following transbronchial biopsy

Prophylactic antibiotics cut risk of infectious complications following transbronchial biopsy

Tisagenlecleucel shows durable activity in R/R aggressive large B-cell lymphomas

Tisagenlecleucel shows durable activity in R/R aggressive large B-cell lymphomas

Statin does not prevent recurrence in high-risk patients undergoing prostatectomy

Statin does not prevent recurrence in high-risk patients undergoing prostatectomy

Family history of Barrett's oesophagus, OAC a strong risk factor for each disease

Family history of Barrett's oesophagus, OAC a strong risk factor for each disease

Lenvatinib-pembrolizumab improves OS, PFS in advanced endometrial carcinoma regardless of DNA MMR status

Lenvatinib-pembrolizumab improves OS, PFS in advanced endometrial carcinoma regardless of DNA MMR status

Apalutamide plus ADT effective against pain, fatigue in metastatic prostate cancer

Apalutamide plus ADT effective against pain, fatigue in metastatic prostate cancer

Pembrolizumab may alter adjuvant treatment landscape of kidney cancer

Pembrolizumab may alter adjuvant treatment landscape of kidney cancer

CLAM in R/R AML: High response rates, effective bridge to allo-HSCT

CLAM in R/R AML: High response rates, effective bridge to allo-HSCT